<DOC>
	<DOCNO>NCT00001018</DOCNO>
	<brief_summary>To determine pharmacokinetic profile single dos letrazuril patient AIDS-related cryptosporidial diarrhea ; determine dose proportionality single escalating dos letrazuril ; determine steady-state concentration letrazuril ; evaluate safety efficacy escalate dos letrazuril , compare placebo , patient AIDS-related cryptosporidial diarrhea . Letrazuril , p-fluor analog diclazuril , show animal model prevent infection organisms closely related intracellular parasite Cryptosporidium . Reliable data need show effectiveness letrazuril treat AIDS-related cryptosporidial diarrhea .</brief_summary>
	<brief_title>A Study Letrazuril Treatment AIDS-Related Diarrhea</brief_title>
	<detailed_description>Letrazuril , p-fluor analog diclazuril , show animal model prevent infection organisms closely related intracellular parasite Cryptosporidium . Reliable data need show effectiveness letrazuril treat AIDS-related cryptosporidial diarrhea . Four group eight patient receive escalate dos oral letrazuril ( placebo ) . In group , six patient randomize receive letrazuril two patient receive match placebo . In pharmacokinetics determination phase study , patient receive single dose letrazuril placebo follow meal . Following 72-hour blood collection , patient enter blind , treatment phase study receive letrazuril placebo single dose daily , meal , 3 week . Patients persistent Cryptosporidium oocysts stools end blind treatment phase may continue open-label treatment letrazuril dose 4 week ; dose may subsequently escalate every 4 week , maximum , oocysts persist . Patients Cryptosporidium oocysts eradicate stools discontinue treatment follow 3 month . All patient undergo clinical follow-up 3 6 month .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Cryptosporidiosis</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antidiarrheal antiemetic medication . AntiHIV agent zidovudine , ddI , ddC dose regimen stable least 3 week prior start study drug . Patients must : AIDS . Chronic diarrhea presence Cryptosporidium oocysts stool specimen . CD4 count &lt; 150/mm3 ( require patient cryptosporidiosis minimum 4 week ) . Life expectancy least 1 month . Prior Medication : Allowed : AntiHIV agent zidovudine , ddI , ddC dose regimen stable least 3 week prior start study drug . Antidiarrheal antiemetic medication . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Grade 4 hematologic toxicity grade 3 toxicity ( patient grade 3 hepatic toxicity may enrol abnormality consider cause biliary cryptosporidiosis ) . Presence diarrheacausing pathogen . Active ( define newly diagnose , progressive , require therapeutic intervention ) opportunistic infection require antimicrobial therapy ( patient receive maintenance prophylactic antimicrobial therapy opportunistic infection may enrol dose regimen stable least 3 week ) . Evidence cytomegalovirus retinitis colitis . Concurrent Medication : Excluded : Ganciclovir , cancer chemotherapy , interferonalpha immunomodulating agent . Any investigational drug ( drug available FDAauthorized expand access program consider investigational ) . Prior Medication : Excluded : Any investigational drug within 1 month prior start study drug ( drug available FDAauthorized expand access program consider investigational ) . Ganciclovir , cancer chemotherapy , interferonalpha immunomodulating agent within 7 day prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 1992</verification_date>
	<keyword>Cryptosporidiosis</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiprotozoal Agents</keyword>
	<keyword>Triazines</keyword>
</DOC>